NCT06380361 (INSPECT) is a NA clinical trial of BioSpy System in Lung Cancer, sponsored by Sensome.

Who is sponsoring NCT06380361?

NCT06380361 is sponsored by Sensome.

What drugs are being tested in NCT06380361?

Interventions in NCT06380361: BioSpy System.

What condition does NCT06380361 study?

NCT06380361 studies Lung Cancer.

Is NCT06380361 still recruiting?

NCT06380361 is currently recruiting now. Last updated 13 January 2025.

Last reviewed 2025-01-13 · How we verify

NCT06380361: INSPECT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

InvestigatioN of a Smart Probe for Lung lEsion Characterization Using Impedance Technology

Recruiting now NA Last updated 13 January 2025

What this trial tests

NA trial testing BioSpy System in Lung Cancer in 30 participants. Currently enrolling.

Timeline

28 March 2024

Primary endpoint
31 March 2025

1 April 2025

Quick facts

Lead sponsor	Sensome
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	30
Start date	28 March 2024
Primary completion	31 March 2025
Estimated completion	1 April 2025
Sites	2 locations across France, Australia

Drugs / interventions tested

BioSpy System

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Sensome — full company profile →

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of the study is to evaluate the feasibility of the BioSpy System sensor to differentiate tissues that are encountered during bronchoscopic biopsy of endobronchial tumors and peripheral lung nodules and masses.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Sensome trials

Trials by the same sponsor.

NCT06112054 — Impedance Sensor Evaluated in Peripheral Artery Disease for Tissue Detection · NA · completed
NCT04993079 — Clotild® Smart Guidewire System (CSGS) Evaluation in EndovascUlar Thrombectomy Procedure · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06380361 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sensome
Last refreshed: 13 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06380361.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing